Novo Holdings Completes Acquisition of Catalent
Novo Holdings has completed its acquisition of Catalent in an all-cash transaction valued at approximately $16.5 billion. Under the deal, Catalent shareholders will receive $63.50 per share, representing a 47.5% premium to the 60-day volume-weighted average price as of February 2, 2024. Following the acquisition, Catalent will operate as a private company, with Alessandro Maselli continuing as President and CEO.
As part of the transaction, Novo Nordisk will acquire three fill-finish sites from Novo Holdings, located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium. Catalent's common stock will be delisted from the New York Stock Exchange.
Novo Holdings ha completato l'acquisizione di Catalent in una transazione interamente in contante valutata circa 16,5 miliardi di dollari. In base all'accordo, gli azionisti di Catalent riceveranno 63,50 dollari per azione, che rappresenta un premio del 47,5% rispetto al prezzo medio ponderato per volume degli ultimi 60 giorni al 2 febbraio 2024. Dopo l'acquisizione, Catalent opererà come azienda privata, con Alessandro Maselli che continuerà come Presidente e CEO.
Come parte della transazione, Novo Nordisk acquisirà tre siti di riempimento e finitura da Novo Holdings, situati ad Anagni, Italia; Bloomington, Indiana, USA; e Bruxelles, Belgio. Le azioni ordinarie di Catalent saranno rimosse dalla Borsa di New York.
Novo Holdings ha completado su adquisición de Catalent en una transacción totalmente en efectivo valorada en aproximadamente 16.5 mil millones de dólares. Según el acuerdo, los accionistas de Catalent recibirán 63.50 dólares por acción, lo que representa una prima del 47.5% sobre el precio promedio ponderado por volumen de los últimos 60 días hasta el 2 de febrero de 2024. Tras la adquisición, Catalent operará como una empresa privada, con Alessandro Maselli continuando como Presidente y CEO.
Como parte de la transacción, Novo Nordisk adquirirá tres sitios de llenado y acabado de Novo Holdings, ubicados en Anagni, Italia; Bloomington, Indiana, EE.UU.; y Bruselas, Bélgica. Las acciones ordinarias de Catalent serán deslistadas de la Bolsa de Nueva York.
노보 홀딩스는 약 165억 달러 규모의 전액 현금 거래로 카탈렌트 인수를 완료했습니다. 이번 거래에 따라 카탈렌트 주주들은 주당 63.50달러를 받게 되며, 이는 2024년 2월 2일 기준으로 최근 60일간의 거래량 가중 평균 가격에 비해 47.5%의 프리미엄을 나타냅니다. 인수 후 카탈렌트는 사기업으로 운영되며, 알레산드로 마셀리가 사장 겸 CEO를 계속 맡게 됩니다.
거래의 일환으로 노보 노디스크는 이탈리아 아난니, 미국 인디애나주 블루밍턴 및 벨기에 브뤼셀에 위치한 노보 홀딩스로부터 3개의 충전 및 마감 사이트를 인수합니다. 카탈렌트의 일반 주식은 뉴욕 증권 거래소에서 상장 폐지될 것입니다.
Novo Holdings a finalisé son acquisition de Catalent dans le cadre d'une transaction entièrement en espèces d'une valeur d'environ 16,5 milliards de dollars. Dans le cadre de cet accord, les actionnaires de Catalent recevront 63,50 dollars par action, ce qui représente une prime de 47,5 % par rapport au prix moyen pondéré par volume sur 60 jours au 2 février 2024. Suite à l'acquisition, Catalent fonctionnera en tant qu'entreprise privée, avec Alessandro Maselli continuant comme Président et CEO.
Dans le cadre de la transaction, Novo Nordisk acquerra trois sites de remplissage et de finition de Novo Holdings, situés à Anagni, en Italie ; Bloomington, Indiana, États-Unis ; et Bruxelles, Belgique. Les actions ordinaires de Catalent seront retirées de la Bourse de New York.
Novo Holdings hat die Übernahme von Catalent in einer vollständig bar bezahlten Transaktion im Wert von rund 16,5 Milliarden Dollar abgeschlossen. Gemäß dem Vertrag erhalten die Aktionäre von Catalent 63,50 Dollar pro Aktie, was einer Prämie von 47,5% gegenüber dem volumengewichteten Durchschnittspreis der letzten 60 Tage zum 2. Februar 2024 entspricht. Nach der Übernahme wird Catalent als privates Unternehmen tätig sein, wobei Alessandro Maselli weiterhin als Präsident und CEO fungieren wird.
Im Rahmen der Transaktion wird Novo Nordisk drei Füll- und Fertigstellungsstandorte von Novo Holdings erwerben, die sich in Anagni, Italien; Bloomington, Indiana, USA; und Brüssel, Belgien befinden. Die Stammaktien von Catalent werden von der New Yorker Börse delistet.
- All-cash transaction provides significant 47.5% premium to shareholders
- Strategic acquisition strengthens Catalent's market position in pharma services
- Continued leadership stability with existing CEO remaining in position
- Private ownership structure may allow for more flexible strategic decisions
- Shareholders lose potential future upside as company goes private
- Delisting from NYSE reduces investment liquidity options
Insights
Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership
Alessandro Maselli, who will remain President and Chief Executive Officer of Catalent, said, “The completion of this transaction marks a significant milestone for Catalent. As a private company with Novo Holdings’ partnership and support, we are well-positioned to deliver unparalleled outcomes for our customers and the patients they serve, and ultimately create value for our stakeholders. I would like to thank all of our employees for their commitment to making Catalent the incredible company it is today, and I am excited for all that we will accomplish going forward.”
Kasim Kutay, CEO of Novo Holdings, said, “We are pleased to welcome Alessandro and the talented Catalent team to the Novo Holdings family. Catalent plays a key role in driving product development, launch and supply solutions for pharma, biotechnology, and consumer health companies, and its mission is closely aligned with Novo Holdings’ purpose to invest for the benefit of people and the planet.”
“We look forward to supporting the Catalent team as they build on their positive momentum and position the company for future growth to the benefit of customers and patients globally,” added Jonathan Levy, Senior Partner, Novo Holdings.
With the completion of the transaction, holders of Catalent common stock are entitled to receive
Shortly following the completion of the transaction, Novo Nordisk A/S will acquire from Novo Holdings Catalent’s three fill-finish sites located in Anagni,
Advisors
Citi and J.P. Morgan served as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to Catalent and Jones Day served as legal advisor to the Catalent Board of Directors. Morgan Stanley & Co. LLC served as financial advisor to Novo Holdings. Goodwin Procter LLP and Linklaters LLP served as legal advisors to Novo Holdings. Davis Polk & Wardwell LLP and Arnold & Porter Kaye Scholer LLP served as legal advisors to Novo Nordisk.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
About Novo Holdings
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth,
About the Novo Nordisk Foundation
Established in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241218507326/en/
Catalent
Investor Contact:
Paul Surdez
+1 (732) 537-6325
investors@catalent.com
Media Contact:
Laura Hortas
+1 (609) 240-7025
media@catalent.com
Novo Holdings
Global media inquiries: Marie-Louise Jersin, Senior Communications Partner
US media inquiries: Dora Gonzalez, Public Relations Specialist
novoholdingsmedia@novo.dk
Source: Catalent, Inc.
FAQ
What is the total value of Novo Holdings' acquisition of Catalent (CTLT)?
How much will Catalent (CTLT) shareholders receive per share in the Novo Holdings acquisition?
Which Catalent (CTLT) facilities will Novo Nordisk acquire after the acquisition?
Will Catalent (CTLT) remain publicly traded after the Novo Holdings acquisition?
Who will lead Catalent (CTLT) after the Novo Holdings acquisition?
